Elevate Your
Stock Analysis

→

$110.9B

Acquisition

Paramount → Warner Bros. Discovery

Media / Entertainment

WBD shareholders voted overwhelmingly to approve Paramount Skydance's $111 billion takeover on 23 April 2026, with 1.743 billion shares in favour and only 16.3 million opposed. WBD shareholders receive $31 per share in cash. The deal clears EU Phase 1 antitrust review on 29 April 2026. Paramount disclosed that the combined company will be 49.5% owned by Middle Eastern sovereign wealth funds — Saudi PIF (15.1%), UAE sovereign fund (12.8%), and Qatar Investment Authority (10.6%) — triggering an FCC Commissioner public demand for heightened scrutiny and a Section 310(b)(4) foreign ownership petition filing by Paramount. Multiple state attorneys general (including New York and California) have issued subpoenas and Civil Investigative Demands as of May 2026. Separately, a judge dismissed Elon Musk's lawsuit against OpenAI on 18 May 2026, removing a parallel distraction. The deal's close — targeting Q3 2026 — hinges on DOJ antitrust clearance, FCC broadcast licence approval for the foreign ownership structure, and resolution of state AG investigations. The combined complexity of these parallel proceedings makes a Q1 2027 close more likely than Q3 2026.

→

$85B

Merger

Union Pacific → Norfolk Southern

Transportation / Infrastructure

Union Pacific's proposed acquisition of Norfolk Southern would create the first transcontinental freight railroad in US history — combining Union Pacific's 32,000-route-mile western system with Norfolk Southern's 19,500-route-mile eastern network into a combined entity to be named The Union Pacific Transcontinental Railroad. The $85 billion enterprise value makes this the largest proposed railroad merger since BNSF in 1995. Management projects $1 billion per year in cost synergies and estimates removal of 2.1 million trucks annually from US highways. The deal holds unusual political support: the SMART-TD railroad union formally backed the combination and President Trump publicly endorsed it. Union Pacific refiled its application with the Surface Transportation Board on 30 April 2026 after the STB found the initial December 2025 filing procedurally incomplete. The STB is expected to rule on completeness by end of May 2026, triggering the start of a multi-year formal review. Union Pacific has indicated it will withdraw if regulators require widespread trackage rights or broad line divestitures beyond one duplicative main line between Kansas City and St. Louis.

→

$34.5B

Acquisition

Charter Communications → Cox Communications

Telecommunications / Cable

Charter Communications is acquiring Cox Enterprises' cable, commercial fiber, and cloud communications businesses for $34.5 billion. The FCC Wireline Competition Bureau approved the deal on 27 February 2026, with conditions including US job preservation, a $20/hour minimum starting wage, and onshoring of all offshore job functions within 18 months. The DOJ and key states including New York and Connecticut have cleared the transaction. California's Public Utilities Commission is the sole remaining regulatory approval — evidentiary hearings concluded 20-24 April 2026 and Charter has formally requested the CPUC to accelerate its review. The federal merger condition deadline is September 15, 2026. The combined company will be the largest US internet service provider with over 37 million broadband subscribers, operating under the Cox name with the Spectrum consumer brand.

→

$33.4B

PE Deal

BlackRock / EQT Consortium → AES Corporation

Energy / Infrastructure

A consortium led by BlackRock's Global Infrastructure Partners and EQT Infrastructure VI signed a definitive agreement on 2 March 2026 to take AES Corporation private for $15 per share in cash — a total equity value of $10.7 billion and enterprise value of $33.4 billion. CalPERS and the Qatar Investment Authority co-invest alongside the lead sponsors. The deal is one of the largest utility privatisations in history, designed to shield AES from public market pressure during a capital-intensive build-out of clean energy generation, battery storage, and data centre power infrastructure to serve hyperscaler demand. AES operates across 15 countries with a growing contracted clean energy and storage backlog. The transaction requires FERC approval, US antitrust clearance, potential CFIUS review of QIA's participation, and an AES shareholder vote. Close is expected in late 2026 or early 2027; the merger agreement extends through June 2027 if regulatory conditions remain unsatisfied.

→

$17B

Acquisition

QXO → TopBuild

Industrials / Building Products

QXO announced a definitive agreement to acquire TopBuild Corp for approximately $17 billion on 19 April 2026 — the largest deal in the building products distribution sector in decades. TopBuild is the largest distributor and installer of insulation and related building products in North America. Under the terms, TopBuild stockholders receive $505 in cash or 20.2 QXO shares per share (approximately 45% cash, 55% QXO stock). The $505 per share represents a 23.1% premium to TopBuild's closing price on April 17, 2026. The deal has been unanimously approved by both boards. On 11 May 2026, QXO published an investor Q&A outlining its strategy to 'own the job site' by leveraging TopBuild's 22,000 daily job-site visits for expanded bundled offerings and inventory optimisation. The combined company will be the second-largest publicly traded building products distributor in North America with over $18 billion in combined revenue and $2 billion in adjusted EBITDA. QXO CEO Brad Jacobs — who previously built XPO Logistics into a $35 billion company — is targeting $50 billion in revenues through an aggressive industry consolidation roll-up. Close is expected in Q3 2026.

→

$11.75B

Acquisition

Sun Pharmaceutical → Organon

Pharmaceuticals

Sun Pharmaceutical Industries signed a definitive agreement on 26 April 2026 to acquire Organon & Co for $14 per share in cash — a total enterprise value of $11.75 billion including assumed debt — in the largest outbound acquisition by an Indian pharmaceutical company in history. Organon, spun out of Merck in 2021, brings Sun Pharma a commercialised biosimilars portfolio (including adalimumab, pegfilgrastim, and bevacizumab), a women's health franchise, and established commercial infrastructure across 140+ markets. An Organon shareholder vote is required; Sun Pharma is arranging a funding mix of euro-denominated bonds and offshore loans. Close is targeted by December 2026 subject to US, EU, and Indian regulatory approvals. The deal will create India's first truly global pharmaceutical company with commercial operations across more than 150 countries.

→

$11.6B

Acquisition

Amazon → Globalstar

Technology / Satellite

Amazon agreed on 14 April 2026 to acquire satellite operator Globalstar in an $11.6 billion all-cash deal at $90 per share, enabling the creation of Amazon Leo — a direct-to-device (D2D) low Earth orbit satellite network. The acquisition gives Amazon proprietary spectrum and direct-to-device technology, replacing its commercial agreement reliance on Globalstar's satellite network. Amazon simultaneously announced a partnership with Apple for Amazon Leo to power satellite-based Emergency SOS and connectivity services for iPhone and Apple Watch — providing large-scale immediate commercial demand. Amazon's satellite deployment roadmap targets service launch in 2028. Close is expected in late 2026 or early 2027, pending FCC spectrum approval and standard antitrust clearance. The merger agreement contains a deadline of April 13, 2027 for completion, extendable to October 2027 and again to April 2028 if regulatory or satellite operational milestones have not been satisfied.

→

$5B

Acquisition

Gilead Sciences → Tubulis

Pharmaceuticals / Oncology

Gilead Sciences announced on 7 April 2026 that it will acquire Tubulis, a Munich-based clinical-stage biotech specialising in next-generation antibody-drug conjugates (ADCs), for $3.15 billion in upfront cash plus up to $1.85 billion in contingent milestone payments — a total deal value of up to $5 billion. The acquisition is expected to close in Q2 2026 (by end of June). Tubulis' two lead programmes — TUB-040 (NaPi2b-directed, targeting ovarian cancer and NSCLC, 59% ORR in platinum-resistant ovarian cancer in Phase 1b/2) and TUB-030 (5T4-directed) — will form the centre of Gilead's ADC innovation platform within its Munich research hub. The deal extends a significant M&A spree for Gilead alongside the concurrent Arcellx ($7.8B) and Ouro Medicines ($2.18B) acquisitions, signalling a decisive strategic pivot toward oncology and immunology representing over $15 billion in combined 2026 acquisition charges.